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Abstract 
 
Background: The use of second-generation antipsychotic (SGA) medication among child and adolescent psychiatric patients 
has increased worldwide in recent years. The increase appears to have been more extensive in the USA than in European 
countries, but the tendency is similar. However, after a peak the use seems to have declined in the USA. Simultaneously with 
the increasing numbers, the duration of SGA use has lengthened, indications have broadened, and off-label use has increased. 
Despite existing follow-up recommendations and evidence for the metabolic adverse effects of SGAs in children, research 
evidence has not translated into clinical practice. 
Objective: The aim of this study was to assess the clinical use and follow-up practices of SGA medication among child 
psychiatric patients of one university hospital in Finland. 
Method: This retrospective patient report-based study was conducted at the Child Psychiatric Clinic of Tampere University 
Hospital, Finland. The study sample consisted of 133 patients who were younger than 13 years when initiating SGA treatment 
and had an ongoing SGA medication during the study period. The study sample was divided into two groups according to 
diagnosis to examine whether there were differences between patients with an autistic or a developmental disorder (F83-84) 
and patients with other psychiatric diagnoses. 
Results: This study showed that SGA use in children younger than 13 years was mainly off-label. Irrespective of diagnosis, 
the most common indication was aggression. Especially children with psychiatric diagnoses other than developmental 
disorders had multiple socio-demographic risk factors and adverse life experiences in their background. The follow-up 
practices were diverse and partly irregular. 
Conclusions: A need for systematic SGA monitoring practices and dialogue between the medical specialities treating children 
and their families is evident.  
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Introduction 
The use of second-generation antipsychotic (SGA) 
medication among child and adolescent psychiatric 
patients has increased worldwide in recent years (1-
5). The increase appears to have been more extensive 
in the USA than in European countries, but the 
tendency is the same (3,6). However, after a peak, 
SGA use seems to have declined in the USA (7,8). At 
the same time, the duration of SGA use in children 
has lengthened, indications have broadened, and off-
label use has increased (3,9,10). The use of SGAs in 
children and adolescents seems to be increasing from 
the age of 7 to 8 years onwards, predominantly in 
male patients (2-5). 
In Finland, the prevalence of antipsychotic use 
among children and adolescents under the age of 18 
years has increased from 4.3 to 6.7/1000 between 
2008 and 2015 (5). Simultaneously, the proportion of 
children and adolescents in this age group using 
antipsychotic medication and having a diagnosis of a 
psychotic disorder or psychotic symptoms decreased 
from 19% to 11% (5). According to the statistics of 
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the Social Insurance Institution of Finland, during 
the same period, prevalence of use among children 
younger than 13 years increased from 1.7 to 
2.8/1000. The three most commonly used SGAs in 
this age group were risperidone, aripiprazole, and 
quetiapine. The number of children younger than 13 
years using these drugs in Finland has steadily 
increased in recent years, and the increase is most 
apparent for aripiprazole (14-fold) and risperidone 
(1.5-fold). However, the proportion of children 
younger than 13 years among all SGA users in 
Finland has remained quite steady (1.4% to 1.6%) as 
the number of all users has also increased (Figure 1). 
According to a recent Finnish study, SGAs were the 
most common medication among child psychiatric 
urgent-care in-patients at Kuopio University 
Hospital, and the use was mostly off-label (11). 
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FIGURE 1. Second-generation antipsychotic use of 0 to 12-year-old children 
and all users in Finland (2008 to 2015) 
 
 
 
The official criteria for SGA use by children 
younger than 13 years vary to some extent among 
countries. In the USA, the Food and Drug 
Administration (FDA) approves aripiprazole, 
quetiapine, and risperidone for the treatment of 
bipolar disorder among children older than 10 years 
(12). Aripiprazole and risperidone are also approved 
for the treatment of irritability associated with autism 
(12). In Finland, only risperidone and ziprasidone are 
approved for children younger than 13 years. 
Ziprasidone is approved for manic episodes of 
bipolar disease in children older than 10 years and 
risperidone for short-term use (≤6 weeks) in the 
treatment of conduct problems in children older than 
five years with developmental disorders or mental 
retardation. As official indications for SGA use are 
scarce, use among children is mostly off-label (2). 
Children and adolescents with autism spectrum 
disorders and intellectual disability represent an 
increasing population treated with SGAs (13). SGA 
use is also common among children with attention 
deficit hyperactivity disorder or disruptive behaviour 
disorders (2,3). SGA medication is also used for 
children and adolescents with various other 
diagnoses – such as psychosis, mood and tic 
disorders, and obsessive compulsive disorder – and 
in symptomatic treatment for aggressive behaviour 
despite the primary diagnosis (1,2,8,10,14). 
When looking at the socio-demographic 
background factors of paediatric patients using SGAs 
in the USA, studies show that the increase in SGA 
use has occurred disproportionately more often 
among publicly than privately insured patients (1,7). 
Those in foster care seem to be especially prone to 
antipsychotic prescriptions among publicly insured 
children (7). Children in foster care have often 
experienced traumatic life events, which are, among 
other individual and environmental factors, known 
risk factors for several mental health disturbances 
(15-17). These kinds of experiences are probably 
more common in children and adolescents treated by 
psychiatric services than in the general population. 
For example, adverse life events were frequent 
among adolescent-aged psychiatric in-patients 
suffering from bipolar disorder type I (58%) and 
catatonia (57%) (18). In a study by Ford et al. (19), in 
a clinical sample of child psychiatry out-patients aged 
four to 18 years, one in three participants had a 
history of exposure to interpersonal violence. 
There is some evidence of the benefits of SGA use 
in children. SGAs, particularly risperidone and 
aripiprazole, have shown to be efficient in the 
treatment of irritability, aggression, self-injury, and 
possibly stereotypic behaviour in autism (20-24). 
SGAs also appear to reduce challenging behaviour in 
the short term among children with intellectual 
disabilities (25). There is some evidence that 
risperidone has an effect on disruptive and aggressive 
behaviour in the short term even among children and 
adolescents with a normal IQ (26,27). Risperidone 
and aripiprazole appear to be promising for treating 
tic symptoms in children with Tourette syndrome 
(28,29). With psychosis or schizophrenia, the efficacy 
of SGAs appears to be similar in children, 
adolescents, and young adults (30-32). Aripiprazole 
also appears to be effective in paediatric bipolar 
disease (30,33). However, the available studies mostly 
cover only the short-term use of SGAs, which 
seldom fits the clinical reality. 
In children, the therapeutic profile and adverse 
effects of SGAs seem to differ from those in adults, 
and children also appear to be more vulnerable than 
adults to some SGA-induced adverse effects (34). 
Sedation, hyperprolactinemia, and metabolic 
disturbances, such as weight gain, dyslipidaemia, and 
hyperglycaemia, are known SGA adverse effects that 
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can have far-reaching consequences through 
metabolic, endocrinological, cardiovascular, and 
psychological effects (34-38). We also know very 
little about the long-term effects of SGAs on the 
developing central nervous system. 
The detected increase in SGA use has induced 
attempts to monitor and improve SGA prescription 
practices around the world (7,39,40). All monitoring 
recommendations emphasize on the appropriate use 
of psychosocial interventions and the regular 
monitoring of metabolic and other adverse effects 
(41). The guidelines of the American Academy of 
Child and Adolescent Psychiatry (AACAP), the 
Canadian Alliance for Monitoring Effectiveness and 
Safety of Antipsychotics in Children (CAMESA), 
and the National Institute for Health and Care 
Excellence (NICE) in the UK include 
recommendations for monitoring and managing the 
adverse effects of SGA in children (Table 1) 
(39,40,42). In Finland, there are national clinical 
guidelines for the treatment of schizophrenia in 
adults, but not for children. Psychotropic 
medications are however, recommended to be 
initiated for children in specialist-level health care 
services (5), with the exception of attention deficit 
hyperactivity disorder medication (methylphenidate). 
 
 
 
TABLE 1. Recommendations for monitoring second-generation antipsychotic treatment according to National Institute for Health and Care 
Excellence (NICE), American Academy of Child and Adolescent Psychiatry (AACAP), and Canadian Alliance for Monitoring Effectiveness and Safety 
of Antipsychotics in Children (CAMESA) (39,40,42) 
  
 
 Follow-ups 
Issued by Baseline  1 2 3 4 
NICE   Weekly (first 6 weeks) 12 weeks 
 
Every 6 months 
 
 
 
Growth 
chart*, 
WHC, RR, 
pulse, fb-
gluc, HbA1c, 
lipids, 
prolactin, 
MD, 
nutritional 
status, diet, 
physical 
activity 
 Growth chart, MD, 
efficacy, side-effects 
Growth chart, MD, RR, 
pulse, fb-gluc, HbA1c, 
lipids, prolactin, 
physical health, 
efficacy, side effects 
Growth chart, MD, WHC, 
RR, pulse, fb-gluc, HbA1c, 
lipids, prolactin, physical 
health, efficacy, side effects 
– 
AACAP   Regular intervals     
Family 
history, 
BMI, WC, 
RR, pulse, 
fb-gluc, 
lipids, MD 
 BMI, RR,  
pulse, fb-gluc (HbA1c if 
needed), lipids†, MD 
– – – 
CAMESA   1, 2, 9 months 3 months  6 months 1 year 
 Growth 
chart, BMI, 
WC, RR, 
NEU, fb-
gluc, 
insulin, 
lipids, 
ASAT, ALAT, 
TSH (with 
quetiapine), 
prolactin 
 Growth chart, BMI, 
WC, RR, NEU 
Growth chart, BMI, WC, 
RR, NEU, fb-gluc, 
insulin, lipids, prolactin 
Growth chart, BMI, WC, RR, 
NEU, fb-gluc, insulin, lipids 
ASAT, ALAT, TSH (with 
quetiapine) 
Same as baseline 
Note. ECG recommendations are not included 
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; fb-gluc, fasting glucose; HbA1c, glycosylated hemoglobin; lipids, blood lipid profile; MD, 
movement disorders; NEU, neurological examination; TSH, thyroid-stimulating hormone; RR, blood pressure; WC, waist circumference; WHC, waist and hip 
circumference 
*Includes weight and height 
†If significant weight changes and/or a family history indicating risk 
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Recommendations and follow-up protocols seem 
to be helpful in clinical work and appear to increase 
monitoring and possibly have an effect on 
prescribing practices (7,43,44). Despite the already 
existing recommendations, there has been a lag in the 
translation of research evidence into clinical practice 
(39,45). Rates of metabolic monitoring of SGA have 
been low according to several studies. Rodday et al. 
(46) found that 66% of psychiatrists reported 
routinely asking about the patient’s medical history, 
92% reported monitoring the patient’s growth, 81% 
reported monitoring the patient’s plasma glucose and 
lipids, 23% reported measuring the patient’s waist 
circumference, and 12% reported monitoring the 
patient’s ECG. Being able to measure vital signs, 
height, and weight on site was associated with a 
higher probability of monitoring height and weight 
(46). In an audit performed in the UK, Pasha et al. 
(44) discovered that for in-patients at a child and 
adolescent mental health unit, the parameters 
measured most often before SGA initiation included 
BMI and hip-to-waist circumference; however, the 
monitoring rate of these measurements was only 
60%. In the USA, many monitoring initiatives have 
taken place in the foster care system, and as a result, 
SGA-treated children in foster care are now more 
likely than other publically insured children to receive 
metabolic monitoring, and, in addition, psychosocial 
interventions (7). Nevertheless, both glucose and 
lipid monitoring failed in 72% of these foster 
children and in 82% of others (7).  
Some children appear to be more vulnerable than 
others in developing metabolic adverse effects, and 
an important goal of an SGA monitoring procedure 
should be to identify as early as possible those 
children who are at particular risk for adverse effects 
(36,47). Some specific genes have already been linked 
with the increased risk of adverse effects with SGAs, 
but there are no gene tests available yet in everyday 
clinical work (47,48). In the light of current evidence, 
screening and monitoring practices should thus be 
emphasized.  
 
Aims of the study 
The aim of this study was to assess the clinical use, 
indications, and follow-up practices of SGA 
medication among child psychiatric patients at 
Tampere University Hospital (TAUH), Finland. This 
study also aims to describe the medical and socio-
demographic background factors of SGA-treated 
children as well as the possible benefits and adverse 
effects of SGA medication. 
 
Method 
This study was conducted at the Child Psychiatric 
Clinic of TAUH and was based on patient reports. 
With a catchment area of approximately half a 
million people, TAUH is one of five university 
hospitals in Finland offering specialist-level health 
care services. The Child Psychiatric Clinic gives in-
patient and out-patient services for children aged 0 
to 12 years. Children aged 13 to 18 years are taken 
care of in adolescent psychiatry, which in Finland is 
a separate speciality. Children with a diagnosis of 
mental retardation are referred to separate services. 
Children are referred to TAUH by the health care 
centres and community hospitals of the district. 
Guidelines are available for the referral practices to 
specialist-level child psychiatric services. During the 
study period (1 October 2013 to 1 October 2014), 
1633 children were treated at the clinic.  
The inclusion criteria for the study were that the 
patient was younger than 13 years when initiating 
SGA treatment, that the medication was initiated at 
the TAUH clinic, and that the SGA medication was 
ongoing during the study period. These criteria were 
met by 133 patients, whose patient reports were 
examined until the date the medication was 
discontinued, the patient was referred to another 
clinic, or until 31 May 2015, whichever came first.  
The first author (K.K.) collected information from 
the patient reports and recorded them. Selected 
patient reports were reviewed by the second author 
(L.P.), who also offered second opinion on request 
from the first author. The data collected from patient 
reports consisted of the patient’s age, the conclusion 
of the cognitive evaluation, and other socio-
demographic and medical factors at the SGA 
initiation phase. The conclusions of cognitive 
evaluations were dichotomized as intelligence within 
normal variation or below, based on patient report 
markings of either the attending physician or a 
psychologist. Information on SGA medication use 
(generic name, duration, reasons for discontinuing or 
changing medication) and other psychotropic 
medications as well as information on the patient’s 
diagnoses and indications (or main symptoms) 
attached to the SGA initiation were collected or 
deduced from the patient reports. The reasons for 
discontinuation or changing the SGA were 
categorized for analyses by the first author as: 
adverse effect, no benefits, adverse effects more 
significant than possible benefits (unfavourable risk–
benefit ratio), symptoms diminished so that the 
medication was no longer needed, and no 
information. In addition, information on the 
psychiatric and other medical history of the patient 
and his/her family was recorded. The possible 
benefits and adverse effects of SGA medication were 
extracted from the physicians’ evaluations recorded 
in the patient reports. The available information of 
possible benefits was classified as: considerable 
Second-generation antipsychotics in children 
 
81 
 
benefit, some benefit, uncertain, no benefit, and no 
information. The adverse effects, such as weight 
gain, and neurological, endocrinological (e.g., 
gynecomastia, menstruation disturbances), and other 
mentioned effects were recorded separately. 
Information concerning the follow-up protocols, 
such as medical evaluations made during the follow-
up period (physical status, weight, and height) and 
possible consultations made by child psychiatrists to 
other medical specialties (e.g., cardiology or 
paediatrics) were recorded. The patient’s age-
adjusted BMI score was calculated at the analysis 
phase from the existing weight and height data (if 
both measurements were available from the same 
time point) using the tables of the new Finnish 
growth references (49). 
To examine whether there were any differences 
between patients having an autism spectrum or 
developmental disorder diagnosis and patients with 
other psychiatric diagnoses, the study sample was 
divided into two groups based on diagnosis using the 
International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision (ICD-10) (50). 
The first group (the PDD/DD group) consisted of 
40 (30%) children with a pervasive developmental 
disorder (F84) diagnosis and seven (5%) patients 
with a diagnosis of mixed specific developmental 
disorders (F83). The second group (the non-
PDD/DD group) consisted of 86 (65%) patients 
with various other diagnoses. Results for the groups 
where there are statistically significant differences are 
reported separately; otherwise, the results are 
reported for the entire sample.  
The results of categorized variables are reported as 
frequencies (percentages or number of cases, as 
appropriate). For normally distributed continuous 
variables, means (M) and standard deviations (SD) 
are given, and for other continuous variables, 
medians and quartiles (Md, Q1, Q3) are reported. For 
testing the significance of differences between the 
PDD/DD and non-PDD/DD group, Pearson’s chi-
squared test, Fisher’s exact test, or the Mann–
Whitney U-test were used, as appropriate. A p-value 
of less than 0.05 is considered significant, and a value 
between 0.05 and 0.10 is considered indicative; values 
up to 0.10 are reported. SPSS v.23 was used for all 
statistical analyses. 
 
Results 
Eighty-one percent of the study sample were boys. 
The mean age at the time of SGA initiation was 9.3 
years (SD, 2.1 years). In the PDD/DD group, the 
children were younger at the time of SGA initiation 
than the children in the non-PDD/DD group (M 8.6 
years, SD, 2.0; and M, 9.7 years, SD, 2.0, respectively; 
p = .002). The age distribution of the patients showed 
two peaks, one during the early years of school (6 to 
8 years) and the second at pre-puberty (11 to 12 
years). Cognitive evaluation was performed for 85% 
of the children, and a conclusion about intelligence 
status was available for all but three of them. Eighty-
one percent of those evaluated had an intelligence 
profile within normal age variation. One patient had 
a diagnosis of mental retardation. Information on 
whether the cognitive evaluation was performed or 
not was lacking in four patient reports. Cognitive 
evaluation was performed more frequently in the 
PDD/DD group than in the non-PDD/DD group 
(96% vs. 78%, p =.010), but there were no statistically 
significant differences between groups in the results 
of the evaluations. Seventy-nine percent of the study 
patients had been treated at least once in their 
lifetime at a psychiatric in-patient ward. 
The most common SGA drug at initiation was 
risperidone (93%). Quetiapine (6%) and aripiprazole 
(2%) were less common. Risperidone was 
indicatively more common than other SGAs in the 
PDD/DD group than in the non-PDD/DD group 
(98% vs. 90%, p = .097). Sixteen percent of the 
patients had their medication switched to another 
SGA once, 6% twice, and two patients three times. 
The most common reasons for switching the SGA 
were adverse effects (52%) and an unfavourable risk–
benefit ratio – that is, the attending physician had 
judged that adverse effects were more significant 
than possible benefits (48%). Thirty-two percent of 
the patients who had their SGA switched had no 
benefits from the initiation drug. In the PDD/DD 
group, there were fewer alterations in SGA 
medications than in the non-PDD/DD group (17% 
vs. 34%, p = .035), and the reason for switching was 
less frequently an adverse effect (31% vs. 73%, p = 
.032). 
 
 
 
Patients who discon-
tinued medication
Duration of SGA medication
(months; median and quartiles)
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All patients
All                 
Non-PDD/DD
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PDD/DD       
p = 0.036
p < 0.001
 
 
FIGURE 2. Duration of second-generation antipsychotic (SGA) medication. 
Figures in the “all patients” group do not describe the genuine duration of 
SGA medication because the duration after the endpoint of the follow-up is 
not known 
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Figure 2 shows the duration of SGA medication in 
this study. Almost one-fifth of the patients 
discontinued medication completely during the study 
period. The median duration of SGA medication 
among these patients was 14.4 months. In the 
PDD/DD group, the duration of SGA treatment 
was longer than in the non-PDD/DD group (Md, 
22.7 vs. 10.8 months, p = .036). The most common 
reasons for discontinuation were that the patient’s 
symptoms had diminished to a level where 
medication was no longer needed (52%) or that the 
risk–benefit ratio was considered unfavourable 
(30%). When taking all study patients into account, 
the median duration of SGA medication by the end 
of the study period was 22.2 months. In the 
PDD/DD group, the duration was longer than in 
non-PDD/DD group (Md, 33.7 vs. 18.4, p < .001). 
However, this figure does not describe the actual 
duration of SGA medication in this group because 
the duration after the end of follow-up is not known.  
 
 
 
TABLE 2. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, diagnoses of second-generation 
antipsychotic (SGA)-treated children (n=133) 
Diagnoses ICD-10 class % 
Hyperkinetic disorders  F90 50 
Conduct/mixed conduct and emotional disorder F91-92 40 
Pervasive developmental disorders F84 30 
Obsessive compulsive disorder F42 13 
Disorders of social functioning with onset specific to childhood and adolescence* F94 13 
Reaction to severe stress/adjustment disorders F43 10 
Tic disorders F95 8 
Emotional disorder with onset specific to childhood F93 7 
Disorders of psychological development F80-82 7 
Depressive episode F32 6 
Bipolar affective disorder  F31 5 
Psychotic disorders  F23, F29 5 
Mixed specific developmental disorders F83 5 
Other mood (affective) disorders F38 5 
Phobic and other anxiety disorders F40-41 3 
Dissociative (conversion) disorders F44 3 
Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence† F98 2 
Eating disorders F50 1 
Unspecified mental retardation F79 1 
Note. Each child could have more than one diagnosis 
ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision 
*Reactive attachment disorder F94.1 (n=5), other childhood disorders of social functioning F94.8 (n=12) 
†Non-organic enuresis F98.0 (n=1), non-organic encopresis F98.1 (n=1) 
 
 
 
 
Polypharmacy was common among the patients in 
the study. Nine patients were simultaneously using 
another antipsychotic medication, most commonly 
(five patients) levomepromazine. The actual rate of 
simultaneous use of two different antipsychotic 
agents was higher due to cross-titration periods when 
switching from one medication to another. Sixty-
eight percent of the study patients had undergone at 
least a short-term treatment trial with some other 
psychotropic medication (not including melatonin) 
in addition to SGA during their treatment at the 
Child Psychiatric Clinic. Fifty-three percent had used 
one medication other than SGA and 14% two or 
three. The use of methylphenidate was more 
common in the PDD/DD group than in the non-
PDD/DD group (79% vs. 58%, p = .022). Twenty-
five percent had had at least a trial with atomoxetine 
and 16% with selective serotonin reuptake inhibitors. 
Fourteen percent of the study patients had had 
benzodiazepines as requisite medication at some 
point of their treatment. Almost two-thirds (63%) of 
the patients had undergone at least a short-term 
melatonin treatment for sleep problems.  
All of the study children had at least one ICD-10 
F-category psychiatric diagnosis (50) at the time of 
SGA initiation and 75% had at least two F diagnoses, 
the maximum being four (Table 2). Children in the 
PDD/DD group had more often comorbid 
disorders, 55% of them having two F category 
diagnoses and 38% having three or four, while the 
respective numbers in the non-PDD/DD group 
were 47% and 19% (p = .001). The most common 
diagnoses in the non-PDD/DD group were F91-92 
(conduct/mixed conduct and emotional disorder; 
49%, n = 42) and F90 (hyperkinetic disorders; 44%, 
n = 38). F91-92 and F31 (bipolar affective disorder) 
diagnoses were more common in the non-PDD/DD 
group than in the PDD/DD group (49% vs. 23%, p 
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= .005, and 8% vs. none, p = .051, respectively). 
Thirty-nine percent of the patients had also at least 
one ICD-10 Z diagnosis (factors influencing health 
status and contact with health services), implying 
multiple environmental factors influencing the 
patient’s mental well-being.  
The indication for SGA initiation was clearly stated 
in 61% of patient reports. In general, indications and 
symptoms were diverse, and 92% of the patients had 
two or more indications or main symptoms. The 
most common indications or core/main symptoms 
for SGA initiation were aggression (in 75% of the 
patients) and behaviour problems (74%) 
independent of diagnosis. Mood swings were a more 
common indication in the non-PDD/DD group 
(24% vs. 9%, p = .035) and sleep problems as 
indication indicatively associated with the PDD/DD 
group (17% vs. 6%, p = .063). The officially 
approved criteria for SGA medication (here 
risperidone, which was the most commonly used 
SGA in this study) use in Finland is short-term 
treatment of conduct problems of children older 
than 5 years with developmental disorders or mental 
retardation. None of the SGA-medicated children in 
this study fulfilled all these criteria. With loose 
interpretation, the 47 (35%) patients in the 
PDD/DD group fulfilled the official criterion for 
diagnosis of developmental disorders or mental 
retardation. Forty-five of these patients also fulfilled 
the criterion for age (> 5 years) and 34 fulfilled the 
indication criterion of aggression/aggressive 
behaviour, but in none of the study patients was the 
medication short-term.
 
 
 
 
 
TABLE 3. Family background of the second-generation antipsychotic-treated children 
 All  
(%) 
PDD/DD  
(%) 
Non-PDD/DD 
(%) 
p 
Family status (n=133)    <.001 
Biological parents 37 57 26  
Parental separation  40 36 42  
Foster home 18 6 24 
 
Other (e.g. adoption) 5 0 8  
Number of siblings (n=126)    NS 
None 21 23 20  
One 38 40 37  
Two or more 41 36 43  
Mother’s working status (n=133)    .018 
Working at least part time 53 68 45  
Other or not known 47 32 55  
Father’s working status (n=133)    NS 
Working at least part time 57 64 54  
Other or not known 43 36 47  
Alcohol/drugs (n=83) 60 44 71 .021 
Psychiatric history of first-degree relatives     
Schizophrenia, bipolar disease or other psychosis 
(n=67) 
33 15 45 .016 
Depression (n=88) 67 61 72 NS 
Suicide (n=133)    NS 
Committed 2 2 2  
At least one attempt 7 2 9  
Child exposed to violence (n=133) 41 30 48 .065 
Exposed to domestic violence 11 4 15  
Been object of physical punishment or other 
domestic violence 
12 13 12  
Both exposed and been object 11 6 13  
Other kind of violence exposure (e.g. war 
experiences) 
8 6 8  
Note. In variables concerning suicide and exposure to violence, missing information was categorized as “no”. In all other variables 
missing information was separated. Therefore, the total number of cases vary by variable 
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The study patients had diverse social stress factors 
and adverse life events in their past (Table 3). Less 
than 40% of the patients had both biological parents 
as caregivers at the time of SGA initiation. Parental 
separation was common (40%), and 18% of the 
patients were in foster care. There was parental 
substance abuse in more than half of the families. A 
family history of psychiatric disorders was recorded 
for 84% of the patients (whereas a family history of 
somatic diseases was recorded for 53% of the 
patients). There was a first-degree family member 
who had a diagnosis of schizophrenia, bipolar 
disease, or other psychosis in one-third of the 
families. Over a half of the patients had a depressed 
family member and about one-tenth had a family 
member who had attempted or committed suicide. 
Exposure to some kind of violence was mentioned 
in 41% of the patient reports. 
The everyday functioning of the patient’s parents 
in the PDD/DD group appeared to be better than 
that in the non-PDD/DD group. About half of the 
mothers and fathers of the study patients were 
working at least part time. However, the employment 
of mothers was statistically significantly more 
common in the PDD/DD group than in the non-
PDD/DD group, and children in the PDD/DD 
group also had both biological parents as caregivers 
more often. In the PDD/DD group, out-of-home 
placements were rarer than in the non-PDD group, 
and there was significantly less parental substance 
abuse and fewer first-degree relatives with bipolar or 
other psychoses. Exposure to violence was also 
indicatively less common in the PDD/DD group 
than in the non-PDD/DD group (see Table 3). 
In 36% of the patient reports, there was no 
information on growth history at the time of SGA 
initiation. When reported, growth history was normal 
in 68% of the patients, while there was some 
deviance (e.g., overweight, slow growth) in the 
remainder prior to SGA initiation. Six patients were 
reported to have been drinking alcohol and five 
patients were reported to be smoking. One of the 
patients had voluntarily told the physician about 
experimental substance use. In general, information 
on the patient’s possible substance use was missing.  
In 81% of the cases, the attending physician 
reported either considerable or at least some benefit 
due to the SGA medication. Three percent had no 
benefits from the SGA medication. In 16% of the 
cases, the possible benefits remained uncertain or the 
information was lacking. In many cases, there was 
also fluctuation in symptoms despite the medication. 
In 28% of the cases, the attending physician reported 
no adverse effects. One adverse effect was reported 
in 32% of the patients and 40% had two or more 
adverse effects. The most frequent adverse effects 
were increased appetite and weight gain, which were 
reported in 36% and 35% of the cases, respectively. 
Somnolence, usually in the SGA initiation phase, was 
reported in 33% of cases and other neurological 
adverse effects in 10% of the patient reports. All 
other reported adverse effects (increased irritation, 
mammillary gland symptoms, disturbances in 
menstrual cycle, urinary symptoms, headaches, 
nosebleeds, abdominal pain or swelling, and loss of 
appetite) were each mentioned at most in 7% of the 
patient reports. 
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FIGURE 3. Physical examination, BMI measurements, and laboratory tests 
performed during the second-generation antipsychotic treatment 
 
 
 
Figure 3 shows a summary of the frequency of 
physical examination, laboratory tests, and BMI 
measurements performed during the study period. At 
SGA initiation (baseline), some kind of physical 
examination other than measurement of height or 
weight was performed on 33% of the patients. 
Almost the same proportion of the patients (29%) 
had no physical examination during follow-up. 
Approximately one-fifth of the patients in the 
longest treatment category (over 24 months) had no 
physical examinations during follow-up. At baseline, 
38% of the patients had their weight measured and 
34% had their height measured. Twenty percent had 
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their height measured once and 69% had their height 
measured twice or more often during the follow-up. 
Weight was measured once in 16% of the patients, 
and 77% had at least two weight measurements 
during the follow-up. Ten (8%) patients had no 
information on weight and fourteen (11%) patients 
had no information on height during the follow-up. 
In some reports, it was mentioned that growth was 
followed elsewhere, but the information did not 
always reach the attending physician. Baseline 
laboratory tests were more frequent than physical 
examination. At baseline, some laboratory tests were 
performed for 67% of the patients and plasma lipids 
and glucose, as indicators of metabolic condition, 
were checked for 55% and 61% of the patients, 
respectively.  
Twenty-five percent of the patients had one and 
10% two or three consultations with a paediatric 
cardiologist during the study period. A consultation 
was most often performed as a paper consultation. 
Indications for consultations were diverse, but 
mostly involved the interpretation of an ECG if the 
psychiatrist considered it aberrant. The cardiologist 
did not find absolute obstacles for SGA use in any of 
the consultations. However, in two patients, 
cardiological adverse effects (prolonged QT interval) 
were mentioned as a reason for discontinuing or 
switching the SGA. Other paediatricians (e.g., 
neurologist or endocrinologist) were consulted at 
least once for 32% of the patients. Nine patients were 
referred to a nutritionist for dietary advice.  
 
Discussion 
In this study we assessed the clinical use of SGAs in 
133 child psychiatric patients aged 12 years or 
younger. Children in the study had multiple 
diagnoses, and polypharmacy was common. Most 
(79%) of the patients had had in-patient treatment, 
reflecting their symptom severity and poor functional 
capacity. Comorbidity was common, with 75% of all 
children receiving more than one psychiatric 
diagnosis. Independently of the diagnoses, the main 
SGA target symptom was aggression; however, the 
indication was clearly stated in only 61% of the 
patient reports. The official indications for SGA 
medication for children younger than 13 years are 
few. Nevertheless, these medications are frequently 
used for varying indications in this age group 
(1,2,8,10,14). In this study, the data were collected 
from a geographically restricted area in Finland. 
However, the findings are in line with previous 
studies (2,10,11). SGA use was mostly off-label, since 
none of the patients fulfilled all of the official 
indication criteria.  
Various studies show that the significant risk for 
metabolic and other SGA-induced adverse effects 
calls for appropriate monitoring (34-38). However, 
the content and schedule of the physical evaluations 
and follow-up practices of SGA medications have 
been diverse in child psychiatric clinical work 
(7,39,44-46), as was also observed in this study. Only 
about one-third of the study patients had undergone 
a physical evaluation at SGA initiation. 
Approximately one-fifth of the patients medicated 
for over 24 months had no physical examination at 
any of the follow-up visits. Furthermore, information 
on growth history was lacking of about one-third of 
the patients. It is also noteworthy that information 
on the child’s family history of somatic diseases, 
which is of importance when assessing risk factors 
associated with, for example, metabolic disorders, 
was often incomplete and less thoroughly 
documented than the family history of psychiatric 
illnesses. 
Evaluating the benefits and risks of SGA 
medication among children is complex. SGA 
treatment for children is often associated with the 
symptomatic treatment of developmental or other 
disorders with a long duration (1,2,8,14,21,22,25). 
The average duration of the SGA medication was 
long in this study as well: the median duration was 
almost two years. Most of the SGA-treated patients 
(81%) in this study had an improvement in their 
symptoms at least to some extent, but symptom 
control seemed at times insufficient. In many cases, 
there was fluctuation in the symptoms despite the 
continuous medication and the possible benefits 
gained at the beginning did not remain so evident in 
the long run. During the early years, biopsychosocial 
development is rapid, and many aspects affect the 
possible symptom development. The two peaks in 
the SGA initiation age observed in this study – the 
first school years and pre-puberty – may both reflect 
times of increasing environmental and social 
demands for the child, and these times are also 
challenging from a family perspective. The many 
other psychotropic medication trials observed in this 
study may also have influenced symptom 
improvement or deterioration. In 16% of the patients 
in this study, the effect of the medication remained 
unclear. Despite this, the medication was often 
continued. The use of systematic assessment 
methods for examining changes in patients’ 
functioning or response to medication was not 
possible in this study due to the source of 
information being patient records, which are often 
incomplete and somewhat unsystematic. Further 
studies on the subject are needed, and systematic 
assessment of functional capacity at the baseline and 
during follow-up should be encouraged.  
In this study, the majority of children medicated 
with antipsychotics had remarkable adverse life 
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events in their background. Parental 
psychopathology and substance use, exposure to 
violence, and major changes in the family 
environment were common, and one in every five 
patients was in foster care. There were, however, 
differences in the background factors of the two 
patient groups: children in the non-PDD/DD group 
had more social stress factors than the children in the 
PDD/DD group. Adverse life events are, among 
other individual and environmental factors, known 
risk factors for mental disturbances in childhood and 
during the whole lifetime (15-17), and emotional 
dysregulation is found to be more common in 
children exposed to repeated or multiple traumas 
(15,16). While psychotropic medication can diminish 
behavioural and emotional symptoms and function 
as an important aid to improve the child’s functional 
capacity, it is apparent that psychosocial support is 
necessary alongside medication. If the treatment plan 
is sufficiently integrated, medication can be a helpful 
aid in learning new skills of behavioural and 
emotional control, and, at best, can function as a 
catalyst for development. However, the sufficiency 
of psychosocial support for children treated with 
SGAs is a cause for concern. In a study by Olfson et 
al. (8), less than one quarter of SGA-treated patients 
aged 1 to 13 years received psychotherapy. In a study 
by Crystal et al. (7) more than one-third of children 
in foster care receiving SGA medication failed to 
receive psychosocial mental health services. 
However, as a result of several initiatives to improve 
the monitoring of SGA treatments in foster care 
children in USA, these children now appear to 
receive not only more adequate metabolic 
monitoring, but also psychosocial mental health 
services at rates higher than children in the general 
Medicaid population (7). This encouraging finding 
further highlights the importance of proper 
monitoring practices in clinical work. In this study we 
did not assess the psychosocial treatment measures 
separately. In specialist level child psychiatric services 
in Finland psychoeducation and therapeutic family 
counselling are, however, an integral element and 
need for other therapeutic interventions is evaluated 
individually for every patient. As psychosocial 
support is often put into practice in homes and 
schools by social or educational services, multi-
professional co-operation is essential. Further studies 
of the subject in SGA treated children are needed. 
 
Continuous dialogue between professionals and 
further education concerning medications and 
follow-up practices is important in child psychiatric 
clinical work. According to recent studies, 
psychiatrists’ attitudes towards SGAs and 
performing physical examinations affect their 
prescribing and monitoring practices (46,51). In 
addition, proper facilities and access to equipment 
for physical evaluation are of importance (46). 
Despite the already existing guidelines (39-42), there 
is still a need to standardize practices concerning 
antipsychotic medication use in psychiatric health 
care units treating children. When treating children 
with medications of long duration that affect both 
physical and mental development, liaisons should be 
encouraged between child psychiatry and paediatric 
medicine and child and adult psychiatry.  
 
Clinical significance 
Results of this study are important for future 
planning of the child psychiatric health care in 
Finland. Children suffering from severe psychiatric 
problems need the most efficient treatment, 
including SGA medication when appropriate. The 
need and use of medication should in all 
circumstances be assessed and reported 
systematically, targeting initiation, response, and 
adverse effects. To improve practice standardization, 
we should further develop easy-to-use follow-up 
protocols that are child and family oriented. When 
treating children with medications of long duration 
and influence on both physical and mental 
development, we should also aim to increase 
dialogue between the medical specialities treating 
children and their families.  
 
Limitations 
The data evaluated in this study were originally 
collected for clinical purposes at a time when there 
were no systematic SGA follow-up procedures 
available in clinical work. The results need to be 
interpreted with caution and more systematic 
research of SGA follow-up practices is needed in the 
future. 
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